AstraZeneca Completes Purchase of Sumitomo Chemical's Stake in AstraZeneca K.K. (Japan)

AstraZeneca Completes Purchase of Sumitomo Chemical's Stake in AstraZeneca K.K. (Japan)

26 March 2014

AstraZeneca today announced it has completed the purchase of Sumitomo Chemical's remaining shares in AstraZeneca K.K.

The purchase was valued at approximately JPY10 billion ($102 million) and gives AstraZeneca control of the entire shareholding of AstraZeneca K.K.

Marc Dunoyer, Chief Financial Officer, AstraZeneca, said: "Our decision to gain full control of AstraZeneca K.K. reinforces our focus on Japan as a key growth platform."

– ENDS –

 

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler             +44 20 7604 8030 (UK/Global)

Vanessa Rhodes            +44 20 7604 8037 (UK/Global)

Ayesha Bharmal             +44 20 7604 8034 (UK/Global)

Michele Meixell                +1 302 885 2677 (US)

Jacob Lund                     +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård                         +44 20 7604 8123      mob: +44 7789 654364

Colleen Proctor               + 1 302 886 1842          mob: +1 302 357 4882

Anthony Brown                +44 20 7604 8067         mob: +44 7585 404943

Jens Lindberg                  +44 20 7604 8414         mob: +44 7557 319729
 

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.